Bioethics News

Next-generation stem cell therapy approved in Europe

The European Commission has given conditional approval next-generation stem cell therapy to the product known as Holoclar to be used in burns to the eyes.

Holoclar is a new cell therapy that is produced using corneal epithelial cells from the patient’s healthy eye, which are then expanded and transplanted in the damaged eye (NatureBiotechnology 33; 224-225,2015).

La entrada Next-generation stem cell therapy approved in Europe aparece primero en Observatorio de Bioética, UCV.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.